UCMC Vaccine Recommendations for Adult Transplant Candidates - Pre-Transplant

- As part of the transplant evaluation review the vaccine history with all candidates for vaccines listed below
 - o Identify which vaccines the candidate HAS received and those which HAVE NOT been received or require a booster
 - o Develop care plan to ensure candidate receives necessary vaccines/boosters PRIOR to transplant
 - o Review status during each encounter with candidate until up to date/complete
- Avoid vaccination for 30 days prior to scheduled living donor transplantations

| Vaccine | Туре | Recommended for Candidates? | Who should receive the vaccine? | Series |
|------------------------------|-----------------|-----------------------------|-----------------------------------|-------------------------------------|
| Hepatitis A | Inactivated | YES | Negative antibody to hepatitis A | 2 doses |
| | | | (Anti-HAV) | (Months 0 and 6) |
| Hepatitis B | Inactivated | YES | | Liver Candidates & Renal |
| | | | | Candidates (on dialysis) |
| | | | Negative for BOTH surface | 4 doses (40 mcg) |
| | | | antibody (HepBsAb) and surface | (Months 0, 1, 2,6) |
| | | | antigen (HepBsAg) | Renal Candidates (no dialysis) |
| | | | | 3 doses (20 mcg) |
| | | | | (Months 0, 1, 6) |
| Influenza | Inactivated | YES | All patients | 1 dose annually |
| | | | | High Dose if > 65yrs of age |
| | Live Attenuated | YES | All patients | 1 dose annually |
| Pneumococcal, 13 valent | | | | 1 dose in lifetime; ideally |
| protein conjugate vaccine | Inactivated | YES | All patients | given before Pneumovax, but |
| (Prevnar 13) | mactivateu | ILS | All patients | at least 1 year after |
| (Flevilai 13) | | | | Pneumovax if not |
| Pneumococcal, 23 valent | | | | 1 dose every 5 years; given at |
| polysaccharide vaccine | Inactivated | YES | All patients | least 2 months after Prevnar |
| (Pneumovax 23©) | | | | least 2 months after Frevilar |
| Tetanus, diphtheria (TD), | | | TD: all patients | Tdap: 1 dose in lifetime |
| Tetanus, diphtheria and | Inactivated | YES | Tdap: if > 19 yrs old and haven't | TD: 1 dose every 5-10 yrs |
| pertussis (Tdap) | | | previously received | |
| Varicella zoster (Shingrix©) | Inactivated | YES | Patients ≥ 50 yrs old | 2 doses |
| | | | | (Months 0 and 2-6) |

Additional information provided in table below however most candidates should have already received as a child or only if special circumstances were/are present. Include as part of transplant evaluation as appropriate

| Vaccine | Туре | Recommended for Candidates? | Who should receive the vaccine? | Series |
|--------------------------------|-----------------|-----------------------------|---|--|
| Polio, inactivated | Inactivated | YES | All patients | 3 doses (Months 0, 1, 6) |
| Human Papilloma Virus (HPV) | Inactivated | YES | Females and males 9 to 26 years of age | 3 doses (Months 0, 2, 6) |
| Neisseria meningitis | Inactivated | YES | All patients 11-18 years, asplenic patients, college students, military | 1 dose |
| Haemophilus influenzae | Inactivated | YES | Often given during infancy, asplenic patients | 2-3 doses |
| Rabies | Inactivated | Not routinely given | Recommended for exposures or potential exposures | IM x 5 doses (Days 0, 3, 7, 14, 28) |
| Measles, mumps, rubella (MMR) | Live Attenuated | YES | College student or >18 yrs and did not get at least one dose as a child | 1 dose |
| BCG | Live Attenuated | Not routine in U.S. | When tuberculosis exposure is unavoidable | 1 dose |
| Smallpox | Live Attenuated | Not routine in U.S. | Patients directly exposed to an individual with smallpox | 1 dose |
| Rotavirus | Live Attenuated | NO | n/a | n/a |

**NOTE: Other vaccines, including travel vaccines (Yellow Fever, Vibrio cholera, Japanese encephalitis) should be discussed with Transplant ID